An improved synthesis of haloacetamidine-based inactivators of protein arginine deiminase 4 (PAD4)
Graphical abstract
Cl-amidine, a haloacetamidine-based PAD4 inactivator, is a lead compound for the development of a novel rheumatoid arthritis therapeutic. Herein we present a cost effective solution phase synthetic route that can be used to generate gram scale quantities of the compound for animal studies.
Section snippets
Acknowledgement
We thank the NIH (GM079357) for financial support.
References and notes (24)
- et al.
Am. J. Hum. Genet.
(2005) - et al.
J. Neurochem.
(2002) - et al.
J. Neurosci. Res.
(2005) - et al.
Invest. Ophthalmol. Vis. Sci.
(2006) - et al.
Curr. Eye Res.
(2006) - et al.
Mol. Carcinog.
(2006) - et al.
Arthritis Res. Ther.
(2004) - et al.
BioEssays
(2003) - et al.
Nat. Genet.
(2003) - et al.
Arthritis Rheum.
(2006)
Rheumatol. Int.
(2007)
Arthritis Res. Ther.
(2005)
Cited by (23)
Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity
2012, Journal of Biological ChemistryCitation Excerpt :However, because we used a solution-based synthesis scheme to generate PAD inhibitors in our study, the paper published by the Thompson group (Causey and Thompson, Tetrahedron Letters, 2008) describing the solution phase synthesis of Cl-amidine should be a more appropriate reference (59) to be cited in addition to Ref. 44.
Protein citrullination: Inhibition, identification and insertion
2023, Philosophical Transactions of the Royal Society B: Biological SciencesRole of citrullination modification catalyzed by peptidylarginine deiminase 4 in gene transcriptional regulation
2017, Acta Biochimica et Biophysica Sinica
Copyright © 2008 Elsevier Ltd. All rights reserved.